AICentralResources
AI Tool Comparison

Comparing as AI Medical Research & Clinical Decision Support
BenevolentAI vs Schrödinger

VS
BenevolentAI official logo and brand icon

BenevolentAI

Enterprise
Visit WebsiteFull Review
Schrödinger official logo and brand icon

Schrödinger

Enterprise
Visit WebsiteFull Review

Verdict by Category

Detailed category analysis is not available for this comparison.
View BenevolentAI View Schrödinger
Feature & Spec Matrix

Detailed Comparison24 Criteria

Complete side-by-side breakdown of specifications, capabilities, and feature parity

Swipe horizontally to compare features
Feature / Spec
BenevolentAI
BenevolentAI
Schrödinger
Schrödinger
Pricing Model
EnterpriseBenevolentAI operates through enterprise pharma collaboration agreements and platform licensing — there is no self-serve access or published pricing. Revenue models include: discovery collaborations with pharma companies (AstraZeneca, Merck) structured as multi-year agreements with upfront fees and milestones; licensing of its knowledge exploration tools as standalone software to pharma R&D organizations; and advancing its own clinical pipeline to inflection points for licensing or co-development. Total funding raised is approximately $1.9B, with the company listed on Euronext Amsterdam (AMS: BAI). Contact BenevolentAI through benevolent.com for partnership and platform licensing inquiries.
EnterprisePhysics-based molecular modeling & drug discovery suite — Academic site licenses & commercial enterprise quotes on sales consultation
Starting Price
Custom / Contact Sales
Custom / Contact Sales
Free Plan & Trial Scope
Difference
No free access — enterprise pharma partnerships and platform licensing via sales team
Academic licensing available at reduced rates; commercial pricing via sales team
User Rating Score
Unrated
Unrated
Ideal Workflow / Use Case
Difference
Pharmaceutical companies and researchers needing AI-powered knowledge mining for novel drug target identification and disease hypothesis generation in complex diseases
Pharmaceutical scientists and computational chemists needing physics-based molecular simulation for drug discovery, lead optimization, and ADMET prediction
Enterprise & Scalability
Difference
Euronext Amsterdam listed (AMS: BAI), $1.9B total raised, in-house wet lab facilities in Cambridge UK, strategic collaborations with AstraZeneca and Merck, HIPAA/GDPR compliant data practices, enterprise licensing for knowledge exploration tools
NASDAQ listed (SDGR), enterprise software licensing with volume pricing, cloud-hosted subscriptions, strategic research collaborations with BMS, Sanofi, and Takeda, dedicated scientific support teams, and academic/government licensing programs
Core Categories
AI Healthcare ToolsAI Research & Education Tools
AI Healthcare ToolsAI Research & Education Tools
Benevolent Platform — AI knowledge graph integrating scientific literature, databases, and experimental data
Difference
BenevolentAI Advantage
Not listed
Target identification and disease hypothesis generation from multimodal biomedical data
Supported
Supported
In-house wet lab facilities in Cambridge UK for AI hypothesis validation
Difference
BenevolentAI Advantage
Not listed
Clinical pipeline: BEN-8744 (Phase 1, ulcerative colitis), BEN-28010 (preclinical, glioblastoma), BEN-34712 (preclinical, ALS)
Difference
BenevolentAI Advantage
Not listed
Strategic collaborations with AstraZeneca and Merck for AI-powered drug target discovery
Supported
Supported
Knowledge exploration tools for pharma partners — licensed separately from drug pipeline
Supported
Supported
Integrated AI + wet lab model: AI generates hypotheses, scientists validate in physical experiments
Difference
BenevolentAI Advantage
Not listed
Multi-disease focus: oncology, rare disease, fibrosis, CNS, immunology, and cardiovascular
Difference
BenevolentAI Advantage
Not listed
Listed on Euronext Amsterdam (AMS: BAI) — $1.9B total raised since founding in 2013
Difference
BenevolentAI Advantage
Not listed
Offices in London HQ, Cambridge wet labs, and New York
Difference
BenevolentAI Advantage
Not listed
FEP+ for industry-leading binding affinity prediction in lead optimization
Difference
Not listed
Schrödinger Advantage
Structure-based drug design, ADMET prediction, and quantum chemistry in one platform
Difference
Not listed
Schrödinger Advantage
Cloud-hosted software subscriptions with 10-15% ACV growth target for 2026
Difference
Not listed
Schrödinger Advantage
Materials science applications: battery design, semiconductors, and specialty chemicals
Difference
Not listed
Schrödinger Advantage
$255.87M revenue in 2025 with 23% growth — NASDAQ listed (SDGR)
Difference
Not listed
Schrödinger Advantage
500+ enterprise customers including top 20 global pharma companies
Difference
Not listed
Schrödinger Advantage
Founded 1990 by Professor Richard Friesner — 34+ years of computational chemistry leadership
Difference
Not listed
Schrödinger Advantage
BenevolentAI icon

BenevolentAI Pros & Cons

Pros

  • Fully integrated AI + wet lab model — unique among AI drug discovery platforms
  • AstraZeneca and Merck partnerships validate the platform's target identification quality
  • In-house wet labs in Cambridge close the loop between AI prediction and biology
  • Euronext Amsterdam listed (AMS: BAI) — $1.9B raised, publicly accountable
  • Phase 1 clinical data for BEN-8744 (ulcerative colitis) represents real clinical progress
  • Multiple disease areas covered: oncology, rare disease, CNS, fibrosis, and immunology
  • Knowledge exploration tools can be licensed separately from drug pipeline

Cons

  • Listed on Euronext Amsterdam (AMS: BAI) — less accessible to US retail investors
  • Clinical pipeline still in early stages — no approved drugs yet
  • Smaller than competitors like Recursion in terms of funding and team size
  • Revenue dependent on collaboration milestones — lumpy and uncertain
  • Wet-lab operations add cost complexity vs. pure software drug discovery peers
Schrödinger icon

Schrödinger Pros & Cons

Pros

  • 34+ years of computational chemistry leadership — most trusted physics-based platform in pharma
  • Bunsen AI co-scientist launched July 2026 — BMS immediately deployed it
  • FEP+ delivers industry-leading accuracy in binding affinity prediction
  • NASDAQ SDGR — $255.87M revenue in 2025, 23% growth, turning profitable in Q2 2026
  • 500+ pharma enterprise customers including BMS, Sanofi, Takeda, Pfizer, and Eli Lilly
  • Materials science applications extend reach to battery, semiconductor, and chemical sectors
  • Cloud-hosted subscriptions eliminate on-premise infrastructure burden

Cons

  • Software is expensive — enterprise pricing puts it out of reach for smaller labs
  • Stock (SDGR) has been under pressure — market cap ~$1B despite strong platform
  • Drug discovery segment revenue is milestone-dependent and lumpy
  • Platform learning curve is steep without computational chemistry background
  • Competition from newer, purely AI-native platforms is intensifying
Head-to-Head Battle Cards

Popular Comparisons

Direct feature matrices, pricing breakdowns, and real-world benchmark duels

All AI Healthcare Tools comparisons
Schrödinger vs Atomwise Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Schrödinger and Atomwise in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
BenevolentAI vs Freed AI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between BenevolentAI and Freed AI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Infermedica vs BenevolentAI Comparison Battle Card - Features, Pricing & Review in AI Healthcare Tools
Direct head-to-head AI tool comparison between Infermedica and BenevolentAI in AI Healthcare Tools featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Healthcare ToolsCompare
Google NotebookLM vs Obsidian Comparison Battle Card - Features, Pricing & Review in AI Research Synthesis & Personal Knowledge Management
Direct head-to-head AI tool comparison between Google NotebookLM and Obsidian in AI Research Synthesis & Personal Knowledge Management featuring side-by-side feature matrix, pricing tiers, and benchmark verdict.
AI Research Synthesis & Personal Knowledge ManagementCompare